Shots:
Recordati has entered into a collaboration & license deal with Moderna to develop & commercialize mRNA-3927 globally for the treatment of propionic acidemia
As per the deal, Moderna will continue to co-develop mRNA-3927 with Recordati, while Recordati will lead global commercialization if approved. In exchange, Moderna will receive $50M upfront, ~$110M in development &…
